{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:51:51Z","timestamp":1761486711434},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,4,24]],"date-time":"2002-04-24T00:00:00Z","timestamp":1019606400000},"content-version":"vor","delay-in-days":844,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Pooling of plasma donations increases the risk for blood\u2010borne infections. In solvent\/detergent (SD)\u2010treated plasma, lipid\u2010enveloped viruses are efficiently inactivated. This method, however, does not affect non\u2010lipid\u2010enveloped viruses. The current study investigated the viral safety of SD\u2010treated plasma (Octaplas) and paid particular attention to the transmission of non\u2010lipid\u2010enveloped viruses.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> The study comprised 343 adults undergoing cardiac surgery. Follow\u2010up was performed 6 to 12 months and 2 years after operation. The sera were tested for hepatitis B surface antigen and specific antibodies against hepatitis A, B, and C; cyto\u2010megalovirus; HIV, human T\u2010lymphotropic virus types I and II; and human parvovirus B19 (B19). A total of 25 batches of SD\u2010treated plasma prepared from Norwegian plasma were used. All batches were tested for hepatitis A virus and B19 by nucleic acid amplification testing and investigated for neutralizing antibodies directed against these viruses.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> In patients who received SD\u2010treated plasma, B19 seroconversion occurred at a rate similar to that in nontransfused patients. No other seroconversions could be ascribed to the transfusion of SD\u2010treated plasma. All 25 SD\u2010treated plasma batches contained neutralizing antibodies against hepatitis A virus and B19. In nucleic amplification testing, all SD\u2010treated plasma batches tested positive for B19, while five demonstrated borderline reactions for hepatitis A virus.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Transfusion of SD\u2010treated plasma was found to be safe with regard to lipid\u2010enveloped viruses. Immune antibodies neutralize viral particles in plasma and are of importance in avoiding clinical disease with the non\u2010lipid\u2010enveloped hepatitis A virus and B19.<\/jats:p>","DOI":"10.1046\/j.1537-2995.2000.40010084.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T22:40:47Z","timestamp":1047508847000},"page":"84-90","source":"Crossref","is-referenced-by-count":56,"title":["Viral safety of solvent\/detergent\u2010treated plasma"],"prefix":"10.1111","volume":"40","author":[{"given":"B.G.","family":"Solheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rollag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Svennevig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Arafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bergerud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,24]]},"reference":[{"issue":"1","key":"e_1_2_6_2_2","first-page":"203","article-title":"Virus inactivation by solvent\/detergent treatment and the manufacture of SD\u2010plasma.","volume":"74","author":"Horowitz B","year":"1998","journal-title":"S\/D-plasma, clinical experience and viral safety. Proceedings of the XXVth Congress of the International Society of Blood Transfusion. Vox Sang"},{"issue":"1","key":"e_1_2_6_3_2","first-page":"207","article-title":"Solvent\/detergent treatment of human plasma\u2014a very robust method for virus inactivation. Validated virus safety of Octaplas.","volume":"74","author":"Biesert L","year":"1998","journal-title":"S\/D-plasma, clinical experience and viral safety. Proceedings of the XXVth Congress of the International Society of Blood Transfusion."},{"issue":"1","key":"e_1_2_6_4_2","first-page":"213","article-title":"Viral safety of blood derivatives by immune neutralization.","volume":"74","author":"Rollag H","year":"1998","journal-title":"S\/D-plasma, clinical experience and viral safety. Proceedings of the XXVth Congress of the International Society of Blood Transfusion. Vox Sang"},{"key":"e_1_2_6_5_2","first-page":"98","article-title":"Self\u2010sufficiency for plasma and plasma proteins in Norway.","volume":"33","author":"Solheim BG","year":"1996","journal-title":"Beitr Infusionsther Transfusionsmed"},{"key":"e_1_2_6_6_2","first-page":"1057","article-title":"[From a registry to a clinical information system. Development of Datacor system at Surgery Department A, Rikshospitalet] (Engl abstract).","volume":"115","author":"Svennevig JL","year":"1995","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_6_7_2","volume-title":"Communicable Disease Report, Norway","year":"1997"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01720514"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113290"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111227.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archinte.1989.00390050111022","article-title":"Clinical manifestations of human parvovirus in adults.","volume":"149","author":"Woolf AD","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.2.257"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1537-2995.2000.40010084.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2000.40010084.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T12:32:12Z","timestamp":1698582732000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1537-2995.2000.40010084.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1046\/j.1537-2995.2000.40010084.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1537-2995.2000.40010084.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}